Publikationen, Präsentationen und Poster
| 17. – 21. September 2021
ESMO Congress 2021 – Virtuell – |
A phase II, open label, multicenter study to investigate the efficacy and safety of domatinostat in combination with avelumab in patients with treatment naïve metastatic Merkel cell carcinoma the MERKLIN 1 studyPoster EMERGE: A phase II trial assessing the efficacy of domatinostat plus avelumab in patients with previously treated advanced DONIMI study – Personalized combinations of neoadjuvant Domatinostat, Nivolumab and Ipilimumab in macroscopic stage III melanoma based on the IFN-gamma signature |
| 8. – 11. September 2021
31. Deutschen Hautkrebskongress – Hybrid – |
Unverblindete, multizentrische Phase-II-Studie zur Untersuchung der Wirksamkeit und Sicherheit von Domatinostat in Kombination mit Avelumab bei Patienten mit nicht-vorbehandeltem, metastasierten Merkelzellkarzinom – die MERKLIN 1 Studie
Unverblindete Phase-II-Studie zur Untersuchung der Wirksamkeit und Sicherheit von Domatinostat in Kombination mit Avelumab bei Patienten mit fortgeschrittenem, nicht resezierbaren/metastasierten Merkelzellkarzinom mit Progress unter einer Anti-PD-(L)1-Antikörpertherapie – die MERKLIN 2 Studie |
| 4. – 8. Juni 2021
ASCO Annual Meeting – virtual – |
Results from the phase Ib of the SENSITIZE trial combining domatinostat with pembrolizumab in advanced melanoma patients refractory to prior checkpoint inhibitor therapy |
| 15. – 17. April 2021
10th World Congress of Melanoma and 17th EADO Congress – virtual – |
Efficacy and safety of domatinostat in combination with avelumab in advanced unresectable/metastatic Merkel Cell Carcinoma patients progressing on anti-PD-(L)1 therapy – MERKLIN 2 study |
| 28. September 2020
Journal of Investigative Dermatology |
The HDAC Inhibitor Domatinostat Promotes Cell Cycle Arrest, Induces Apoptosis and Increases Immunogenicity of Merkel Cell Carcinoma Cells
Lina Song, Anne Catherine Bretz, Jan Gravemeyer, Ivelina Spassova, Shakhlo Muminova, Thilo Gambichler, Ashwin Sriram, Soldano Ferrone, Jürgen C. Becker doi: 10.1016/j.jid.2020.08.023 |
| 28. September 2020
Research Outreach, Health & Medicine |
A New Weapon to Boost Cancer Immunotherapy
Svetlana Hamm Ph.D |
| 17. – 21. September 2020
ESMO Kongress 2020 – virtual – |
A phase II, open label study to investigate the efficacy and safety of domatinostat in combination with avelumab in patients with advanced unresectable/metastatic Merkel Cell Carcinoma progressing on anti-PD-(L)1 antibody therapy – the MERKLIN 2 study |
| 8. November 2019
Journal for ImmunoTherapy of Cancer |
Domatinostat favors the immunotherapy response by modulating the tumor immune microenvironment (TIME)
Anne Catherine Bretz, Ulrike Parnitzke, Kerstin Kronthaler, Tobias Dreker, René Bartz, Frank Hermann, Astrid Ammendola, Tanja Wulff and Svetlana Hamm Journal for ImmunoTherapy of Cancer; 2019 Nov 8;7(1):294.; doi: 10.1186/s40425-019-0745-3 |
| 21. – 22. Oktober 2019
1st International Symposium on Merkel Cell Carcinoma Tampa, Florida, USA |
Preclinical rationale and clinical design for the combination of domatinostat with avelumab in Merkel Cell Carcinoma patients: the MERKLIN 1 and MERKLIN 2 studies |
| 27. September – 1. Oktober 2019
ESMO Kongress 2019 Barcelona, Spanien |
Phase Ib/II Study (SENSITIZE) assessing safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical outcome of domatinostat in combination with pembrolizumab in patients with advanced melanoma
EMERGE: Epigenetic Modulation of the Immune Response in Gastrointestinal Cancers |
| 29. März – 3. April 2019
AACR 2019 Atlanta, Georgia, USA |
Domatinostat increases apoptosis, G2M cell cycle arrest and immunogenicity of Merkel cell carcinoma
Tumor abscopal responses induced by the TLR9 agonist, SD-101, are strongly potentiated by a HDAC class I inhibitor, Domatinostat |
| 29. November – 1. Dezember 2018
Melanoma Bridge 2018 Neapel, Italien |
Phase Ib cohort 1 data of class I HDAC inhibitor 4SC-202 (domatinostat) in combination with pembrolizumab in advanced cutaneous melanoma patients refractory or non-responding to prior anti-PD1 therapy |
| 28. – 29. November 2018
Immunotherapy Bridge 2018 Neapel, Italien |
Domatinostat’s impact on tumor immunophenotype and response to PD-(L)1 and LAG-3 blockade in pre-clinical models |
| 22. Oktober 2018
European Journal of Haematology |
Phase I Study of Domatinostat (4SC‐202), a class I Histone Deacetylase Inhibitor in Patients with Advanced Hematological Malignancies
Bastian von Tresckow, Cyrus Sayehli, Walter E. Aulitzky, Maria‐Elisabeth Goebeler, Matthias Schwab, Eunice Braz, Babett Krauss, Rolf Krauss, Frank Hermann, René Bartz, Andreas Engert European Journal of Haematology; 2018 Oct 22; doi: 10.1111/ejh.13188 |
| 19. September – 22. September 2018
SIC Annual Meeting 2018 Mailand, Italien |
4SC-202 (domatinostat), a novel histone deacetylase inhibitor, improves chemotherapy efficacy and overcomes drug resistance in pancreatic cancer models |
| 05. Juli – 06. Juli 2018 Cancer Epigenetic Therapies Conference Neapel, Italien |
Domatinostat (4SC-202) as a core immune-modulatory combination partner for immunotherapy |
| 14. April – 18. April 2018 AACR 2018 Chicago, Illinois, US |
4SC-202 primes tumor microenvironment for treatment with cancer immunotherapy |
| 19. März – 21. März 2018 ITOC5 Conference 2018 Berlin, Deutschland |
4SC-202 increases CTLs in tumor microenvironment and primes tumors for checkpoint therapy.4SC-202 increases CTLs in tumor microenvironment and primes tumors for checkpoint therapy. |
| 05. März – 07. März 2018 TAT 2018 – Targeted Anticancer Therapies Paris, Frankreich |
4SC-202 plus Anti-PD1: Breaking PD1-refractoriness to increase efficacy of checkpoint inhibition in patients with advanced melanoma |
| 30. November – 02. Dezember 2017 Melanoma Bridge Neapel, Italien |
4SC-202 plus Anti-PD1: Breaking PD1-refractoriness to increase efficacy of checkpoint inhibition in patients with advanced melanoma |
| 29. – 30. November 2017 Immunotherapy Bridge Neapel, Italien |
4SC-202 induces inflamed tumor microenvironment, strongly enhances tumor infiltration with cytotoxic T cells and primes tumors for anti-PD-1/PD-L1 therapy |
| 12. – 13. Oktober 2017 3rd Annual Epigenetics Discovery Meeting London, Vereinigtes Königreich |
Modulation of the tumor microenvironment by epigenetic intervention |
| 27. – 28. September 2017 11th Annual Next-Generation Histone Deacetylase Inhibitors Boston, MA, USA |
Epigenetic Priming with New HDAC Class I Inhibitor 4SC-202 Sensitizes Tumor for Anti-PD-1/PD-L1 Therapy |
| 21. – 23. September 2017 27. Deutscher Hautkrebskongress, ADO-Jahrestagung Mainz, Deutschland |
4SC-202 + Pembrolizumab: “SENSITIZE” the tumor to overcome PD-1 refractoriness and increase efficacy of checkpoint inhibition in patients with advanced melanoma |
| 8. – 12. September 2017 ESMO 2017 Conference Madrid, Spain |
4SC-202 plus Anti-PD1: Breaking PD1-refractoriness to increase efficacy of checkpoint inhibition in patients with advanced melanoma |
| 1. – 5. April 2017 AACR Annual Meeting 2017 Washington, D.C., USA |
4SC-202 induces inflamed tumor microenvironment, strongly enhances tumor infiltration with cytotoxic T cells and primes tumors for anti-PD-1/PD-L1 therapy PosterCombination of 4SC-202 and IFN-γ restores mature APC phenotype in AML cells Poster |
| 27. März 2017 Nucleic Acids Research |
Histone deacetylase class-I inhibition promotes epithelial gene expression in pancreatic cancer cells in a BRD4- and MYC-dependent manner. Mishra VK, Wegwitz F, Kosinsky RL, Sen M, Baumgartner R, Wulff T, Siveke JT, Schildhaus HU, Najafova Z, Kari V, Kohlhof H, Hessmann E, Johnsen SA. Nucleic Acids Res. 2017 Mar 27. doi: 10.1093/nar/gkx212. |
| Dezember 2016 Targeted Oncology |
Evaluation of the Therapeutic Potential of the Novel Isotype Specific HDAC Inhibitor 4SC-202 in Urothelial Carcinoma CellLines.
Pinkerneil M, Hoffmann MJ, Kohlhof H, Schulz WA, Niegisch G. Target Oncol. 2016 Dec;11(6):783-798. |
| 30. November – 2. Dezember 2016 4th Max Planck Freiburg Epigenetics Meeting Freiburg, Deutschland |
4SC-202 induces differentiation of AML cells by upregulating promoter histone acetylation |
| 29. November – 2. Dezember 2016 EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium München, Deutschland |
4SC-202: Epigenetic modulator and potential combination partner for checkpoint inhibitors |
| 8. September 2016 2nd Annual Epigenetics Discovery Congress London, Vereinigtes Königreich |
Regulation of tumor microenvironment by the HDAC/LSD1 inhibitor 4SC-202 |
| 16. Juni 2016 World Preclinical Congress – Cancer Immonotherapy and Combinations Congress Boston, USA |
Epigenetic therapeutics for combination with cancer immunotherapy |
| 6. Juni 2016 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO) Chicago, USA |
Novel LSD1/HDAC inhibitor 4SC-202 shows in a mouse model that it is an effective combination partner for checkpoint inhibitors |
| 21. März 2016 3rd Immunotherapy of Cancer Conference München, Deutschland |
A novel LSD1/HDAC inhibitor 4SC-202 inhibits immunosuppression and enhances immunogenicity of tumor cells in vitro and modifies tumor microenvironment in vivo |
| 8. November 2015 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference Boston, USA |
The small molecule inhibitor 4SC-202 controls aberrant HH signaling in cancer |
| 2. Juni 2014 2014 Annual Meeting of the American Society of Clinical Oncology (ASCO) Chicago, USA |
First-in-human study of 4SC-202, a novel oral HDAC inhibitor in advanced hematologic malignancies (TOPAS study) |
| Februar 2014 Molecular Medicine Tri-Conference, Cancer Stem Cell Symposium San Francisco, USA |
Targeting cancer stem cells with 4SC-202 – an epigenetic WNT and HH inhibitor |
| Februar 2014 Keystone Symposia Stem Cells and Cancer Banff, Canada |
4SC-202 – a novel epigenetic modulator to target cancer stem cells |
| November 2013 GTC 3rd Cancer Epigenetics Conference San Francisco, USA |
4SC-202 – A Novel Epigenetic Modulator to Target Cancer Stem Cells |
| 8. – 9. November 2012 2nd Cancer Epigenetics Conference Boston, USA |
4SC-202 – A Novel Epigenetic Modulator to Target Cancer Stem Cells |
| 16. – 19. November 2010 22nd EORTC-NCI-AACR Symposium Berlin, Deutschland |
Preclinical characterization of 4SC-202, a novel isotype specific HDAC inhibitor |